biotech · Malignant Glioma · Prostate Cancer · CADL
Candel Therapeutics
Candel Therapeutics is a biotech organization headquartered in Needham, USA. It trades on NYSE under ticker CADL. Primary therapeutic focus areas include Malignant Glioma, Prostate Cancer, Glioma, Malignant, Pancreatic A
117 Kendrick Street, Suite 450, Needham, Massachusetts 02494, US HQ
1999 Founded
82 Employees
Public company Type
CADL · NYSE Ticker
Company details
- Status
- Public
- HQ
- 117 Kendrick Street, Suite 450, Needham, Massachusetts 02494, US
- Founded
- 1999
- Employees
- 82
- Programs
- 12
- Drugs
- 4
- Patents
- 0
aglatimagene besadenovec + valacyclovir
Phase 2 · mab · Prostate Cancer Patients Treated by Radiotherapy
aglatimagene besadenovec + valacyclovir for Prostate Cancer Patients Treated by Radiotherapy is a Phase 2 program (mab) at Candel Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code PrTK05
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Candel Therapeutics
- Phase
- Phase 2
- Modality
- mab
- Indication
- Prostate Cancer Patients Treated by Radiotherapy
- Status
- active
- Trials
- 1